Patents by Inventor Satoshi UMEZAKI
Satoshi UMEZAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11465965Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 2, 2018Date of Patent: October 11, 2022Assignee: UBE INDUSTRIES, LTD.Inventors: Haruka Yamada, Ken-ichi Komori, Yusuke Shiraishi, Satoshi Umezaki, Naoya Kinoshita, Koji Ito, Tomoko Kanda, Kenji Yoneda, Yasunori Tokunaga, Tomio Kimura
-
Patent number: 10968238Abstract: Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.Type: GrantFiled: October 30, 2018Date of Patent: April 6, 2021Assignee: UBE INDUSTRIES, LTD.Inventors: Noriaki Iwase, Shigeyuki Kono, Masayuki Tanaka, Masaaki Matoyama, Satoshi Umezaki, Yusuke Shiraishi, Masahiro Kojima, Hayato Nishiyama
-
Patent number: 10894798Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.Type: GrantFiled: April 3, 2019Date of Patent: January 19, 2021Assignee: UBE INDUSTRIES, LTD.Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
-
Publication number: 20200347011Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 2, 2018Publication date: November 5, 2020Applicant: UBE INDUSTRIES, LTD.Inventors: Haruka YAMADA, Ken-ichi KOMORI, Yusuke SHIRAISHI, Satoshi UMEZAKI, Naoya KINOSHITA, Koji ITO, Tomoko KANDA, Kenji YONEDA, Yasunori TOKUNAGA, Tomio KIMURA
-
Publication number: 20190256531Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.Type: ApplicationFiled: April 3, 2019Publication date: August 22, 2019Applicant: UBE INDUSTRIES, LTD.Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
-
Patent number: 10273252Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.Type: GrantFiled: June 14, 2016Date of Patent: April 30, 2019Assignee: UBE INDUSTRIES, LTD.Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
-
Publication number: 20190062353Abstract: Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Applicant: UBE INDUSTRIES, LTD.Inventors: Noriaki IWASE, Shigeyuki KONO, Masayuki TANAKA, Masaaki MATOYAMA, Satoshi UMEZAKI, Yusuke SHIRAISHI, Masahiro KOJIMA, Hayato NISHIYAMA
-
Patent number: 10131679Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.Type: GrantFiled: October 30, 2015Date of Patent: November 20, 2018Assignee: UBE INDUSTRIES, LTD.Inventors: Yasuhiro Aga, Shigeru Ushiyama, Noriaki Iwase, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Masayuki Tanaka, Masaaki Matoyama, Satoshi Umezaki, Yusuke Shiraishi, Kazuhiro Onuma, Masahiro Kojima, Hayato Nishiyama, Tomio Kimura
-
Publication number: 20180186818Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.Type: ApplicationFiled: June 14, 2016Publication date: July 5, 2018Applicant: UBE INDUSTRIES, LTD.Inventors: Noriaki IWASE, Yasuhiro AGA, Shigeru USHIYAMA, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Satoshi UMEZAKI, Masahiro KOJIMA, Kazuhiro ONUMA, Yusuke SHIRAISHI, Makoto OKUDO, Tomio KIMURA
-
Publication number: 20170313727Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.Type: ApplicationFiled: October 30, 2015Publication date: November 2, 2017Applicant: UBE INDUSTRIES, LTD.Inventors: Yasuhiro AGA, Shigeru USHIYAMA, Noriaki IWASE, Shigeyuki KONO, Hidetoshi SUNAMOTO, Takashi MATSUSHITA, Sayaka OGI, Masayuki TANAKA, Masaaki MATOYAMA, Satoshi UMEZAKI, Yusuke SHIRAISHI, Kazuhiro ONUMA, Masahiro KOJIMA, Hayato NISHIYAMA, Tomio KIMURA